PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-20.40%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-20.40%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-19.78%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
12.20%
EPS growth above 1.5x AGEN's 0.18%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
12.20%
Diluted EPS growth above 1.5x AGEN's 0.18%. David Dodd would see if there's a robust moat protecting these shareholder gains.
35.62%
Share count expansion well above AGEN's 8.00%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
35.62%
Diluted share count expanding well above AGEN's 8.00%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-10.71%
Negative OCF growth while AGEN is at 15.38%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-10.88%
Negative FCF growth while AGEN is at 15.58%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-812.85%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
87.84%
5Y OCF/share CAGR above 1.5x AGEN's 18.70%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
86.67%
3Y OCF/share CAGR above 1.5x AGEN's 33.85%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
-1279.04%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
88.03%
Positive 5Y CAGR while AGEN is negative. John Neff might view this as a strong mid-term relative advantage.
86.27%
3Y net income/share CAGR above 1.5x AGEN's 24.07%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
1371.24%
Positive growth while AGEN is negative. John Neff might see a strong advantage in steadily compounding net worth over a decade.
-83.09%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-60.87%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-9.71%
Negative asset growth while AGEN invests at 10.06%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-34.03%
We have a declining book value while AGEN shows 15.46%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-19.69%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
7.98%
We increase R&D while AGEN cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
58.15%
SG&A growth well above AGEN's 1.30%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.